Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan

The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio

Astellas, BioLabs and Mitsui Fudosan collaborate to enhance life science ecosystems in Tsukuba and Kashiwa-no-ha, Japan

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent

Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData

In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1

Astellas submits new drug application for Zolbetuximab in Japan

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers

Health Minister Mandaviya invites Japanese pharma companies to invest in India

The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Japan approves ENHERTU for treatment of adult patients with HER2 positive unresectable breast cancer

Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial

AGC begins study to expand its Bio-CDMO capability in Japan